Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

Item

http://www.wikidata.org/entity/Q30451184

Q30451184

about

Iota-Carrageenan is a potent inhibitor of rhinovirus infection Respiratory viruses other than influenza virus: impact and therapeutic advances Design of wide-spectrum inhibitors targeting coronavirus main proteases Roles of the Picornaviral 3C Proteinase in the Viral Life Cycle and Host Cells Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Structural Basis for Antiviral Inhibition of the Main Protease, 3C, from Human Enterovirus 93 3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus Altered Innate Immune Responses in Neutrophils from Patients with Well- and Suboptimally Controlled Asthma Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.Human rhinoviruses.The infectious march: the complex interaction between microbes and the immune system in asthma.Respiratory viral infections in children with asthma: do they matter and can we prevent them?Anthracene-based inhibitors of dengue virus NS2B-NS3 protease An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation.Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production Role of viral infections in asthma and chronic obstructive pulmonary disease.Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease Host immune responses to rhinovirus: mechanisms in asthma.Human challenge studies: a review of adequacy of reporting methods and results.Toward antiviral therapy/prophylaxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies.Enteroviral proteases: structure, host interactions and pathogenicity.Antiviral therapy for respiratory viral infections in immunocompromised patients.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Real-time quantitation of viral replication and inhibitor potency using a label-free optical biosensor.Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections.Hepatitis A virus proteinase 3C binding to viral RNA: correlation with substrate binding and enzyme dimerization.The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir.Infection and propagation of human rhinovirus C in human airway epithelial cells.Human rhinovirus group C in hospitalized children, Singapore.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.Lack of respiratory and contact sensitizing potential of the intranasal antiviral drug candidate rupintrivir (AG7088): a weight-of-the-evidence evaluation.Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro.Respiratory viral infections in high-risk patients.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Emerging antiviral drugs

P2860

Q21245131-F0A9DB51-E774-4BE5-89B9-5E9BC5870328 Q24655957-2F8937D9-CC4B-4EDF-9D63-AE9989683998 Q24817106-3CE61C18-8A0A-432B-A74E-D21B8A07B862 Q26753001-A19A8F02-093C-42DB-8FE8-B4101E8922B3 Q26822988-E7C7B790-1F45-4A98-B362-DF6CE9D5FAD1 Q27671687-1EF620A1-D4B4-4C27-BE6C-4744A885A2DE Q27676219-759EAAA4-8F2B-4524-B949-2170F57061C2 Q27684137-2E21980B-A410-4DB6-9B62-83BB3C48215F Q28395377-F231CED2-7D59-4E42-A429-075498D9ADEB Q30431675-0A3F27D8-1F33-4574-B247-A05C7255A644 Q30443266-926B929B-02AD-432B-B9F9-517AF321FC33 Q30448335-20057F23-094F-4587-9B06-F71C57C25DFD Q30448643-436CE0E9-C728-46AB-BF7D-05F5C0466F2C Q34321393-727F0B6A-D0E8-4C47-A4A2-F3AAFD45771A Q34356430-FF51429C-03DC-4100-AB24-FE9A3C525C14 Q34413913-C4171FB1-B5D9-48C0-B417-F9636877ADC9 Q34516819-8E9A89EC-92AB-492C-A7B6-9C7638EE5372 Q34916830-D0E737A5-5F9F-4BF0-8CA1-11033598FB15 Q35023969-78EF6902-EC8F-4677-A6C4-FFF1309A4F10 Q36508226-9D0A9980-3E7D-4CA0-A818-1C971FB17278 Q37029615-CD850014-4942-42B4-B928-8CADFE1774A3 Q37267466-45088D38-F3A7-4B05-874A-F378A486D0B8 Q37327666-CF47A2CB-4FDD-4AD9-BBCA-AC5E21D7AC83 Q37996090-350029FA-DE07-480C-AA17-CD5EB2980C1F Q38590038-F733DBEC-AAE1-494F-B981-952D425D80D9 Q38825350-99637416-D477-4C9D-B579-9C6B2855F9DC Q39076394-24E28498-2A1D-4500-9B28-1238C9ACF5B3 Q39444008-08F4F883-B939-4C71-894A-77D8898C5C28 Q39819359-B18BDA0D-51B0-48AF-9899-887F0269C3F5 Q39855616-9616D8A1-2733-4BF2-BFCE-F342C5219EB1 Q40516783-580BD469-4CC4-4949-872C-977BFE1D516A Q41175433-9979CE9F-926B-408F-90A7-EE69FE682575 Q41648187-547FD22A-031C-4F17-B238-394DE14E68C6 Q42924059-3C6D0272-8B9C-4326-ADFD-553D824A53F2 Q42981047-76FCD340-E76D-4AE0-A864-CAA59967E35F Q43563933-89A2B49C-B5C7-4B8E-9AB6-0B90E92EF693 Q46103147-07625F74-10B8-4F4E-8FAF-C7CF1EA4CB7B Q47890232-F758488D-9597-4F5D-B97E-4D8C8AD13EA2 Q55447639-5F1B7E58-B084-43B8-A215-FC4E76A9CCAB Q56786308-A8F27D0C-C653-44C0-B273-04C2B9E3B0EE

P2860

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

Item

http://www.wikidata.org/entity/Q30451184

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu